Avaliação dos efeitos cardiovasculares do imatinibe em pacientes com leucemia mielóide crônica
=== Background: Imatinib mesylate (IM), a tyrosine kinase inhibitor that targets BCR-ABL, PDGFRA and c-kit, has become the first line of therapy for patients with chronic myeloid leukemia (CML) and advanced gastrointestinal stromal tumors (GIST). A recent publication suggests that IM might have myo...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | Portuguese |
| Published: |
Universidade Federal de Minas Gerais
2008
|
| Online Access: | http://hdl.handle.net/1843/ECJS-7EUK6U |